Eli Lilly and Company
LLY · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $695 | $524 | $348 | $263 |
| - Cash | $3 | $3 | $2 | $4 |
| + Debt | $34 | $25 | $16 | $17 |
| Enterprise Value | $726 | $547 | $362 | $276 |
| Revenue | $45 | $34 | $29 | $28 |
| % Growth | 32% | 19.6% | 0.8% | – |
| Gross Profit | $37 | $27 | $22 | $21 |
| % Margin | 81.3% | 79.2% | 76.8% | 74.2% |
| EBITDA | $15 | $9 | $9 | $8 |
| % Margin | 33.8% | 25.1% | 30.3% | 28.4% |
| Net Income | $11 | $5 | $6 | $6 |
| % Margin | 23.5% | 15.4% | 21.9% | 19.7% |
| EPS Diluted | 11.71 | 5.8 | 6.57 | 5.85 |
| % Growth | 101.9% | -11.7% | 12.3% | – |
| Operating Cash Flow | $9 | $4 | $8 | $7 |
| Capital Expenditures | -$8 | -$7 | -$3 | -$2 |
| Free Cash Flow | $0 | -$3 | $5 | $5 |